Innorna, a Chinese biotech largely based in Shenzhen, won FDA clearance to begin a Phase 1 study of an mRNA therapy for refractory gout, the company told Endpoints News in an exclusive interview.
If successful …
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win
Pfizer said a combination of two of its prostate cancer drugs — Talzenna and Xtandi — succeeded in a Phase 3 study and that it


